Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Nov 14, 2023 12:39pm
118 Views
Post# 35734692

RE:RE:Led by a healthcare focused institutional investor

RE:RE:Led by a healthcare focused institutional investorVery little doubt now that MC is a truly awful CEO.

Anson short sells ONC for a month or so and when they need to cover their shorts they simply call MC and arrange for a well below market purchase of shares.

And MC says, sure, we could really use the money, to pay our wages, thanks and by the way screw all the long term shareholders, who cares about them.

And ONC issues a deceptive press release suggesting the shares went to a healthcare focused investor.

BTW, ONC would never have done this had they not already had some very strong idea that PanCAN was near collapse.

Truly awful management of a sh*tty little micro cap biotech.

Doubtful this will ever enter P3 for any indication.

They'll keep running P2's until MC has enough money saved up for a very comfortable retirement.

<< Previous
Bullboard Posts
Next >>